<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773795</url>
  </required_header>
  <id_info>
    <org_study_id>CL00003</org_study_id>
    <nct_id>NCT04773795</nct_id>
  </id_info>
  <brief_title>Evaluation of EndoZip System in Obese Patients Who Failed to Reduce Weight With Non-surgical Weight-loss Methods</brief_title>
  <official_title>Evaluation of EndoZip System in Obese Patients Who Failed to Reduce Weight With Non-surgical Weight-loss Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitinotes Surgical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitinotes Surgical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, prospective, single-arm, open-label, controlled clinical trial aimed to&#xD;
      evaluate the safety and effectiveness of the EndoZip system procedure, coupled with lifestyle&#xD;
      modifications, for weight reduction in obese patients with BMI of 30-40 kg/m2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      study will include up to 45 (10-20 patients per site), ages of 21 -70 of obese patients who&#xD;
      failed to reduce weight with non-surgical weight-loss methods.&#xD;
&#xD;
      The duration for each participant will be 12 months and will include the following follow up&#xD;
      visits and procedures:&#xD;
&#xD;
        -  Office visits: screening, 1 week, and 1, 2, 4, 6, 8, 10, and 12 month(s)&#xD;
&#xD;
        -  Remote follow up (by Phone): 3, 5, 7, 9, and 11 month(s)&#xD;
&#xD;
        -  Endoscopy procedure: baseline, 2 and 6 months post EndoZip procedure&#xD;
&#xD;
        -  Motility evaluation by Gastric Emptying Breath Test (GEBT): baseline, 6 months&#xD;
&#xD;
        -  Physical examination, vital signs, waist circumference and BMI: baseline, 1 week, 1, 2,&#xD;
           4, 6, 8, 10 and 12 months&#xD;
&#xD;
        -  Blood tests: baseline,2, 6 and 12 months&#xD;
&#xD;
        -  IWQOL-Lite: baseline, 2, 6 and 12 months&#xD;
&#xD;
        -  Psychological health questionnaire-9 (PHQ-9) :baseline&#xD;
&#xD;
        -  Sleep Apnea (only for the relevant population): baseline 2, 6 and 12 months&#xD;
&#xD;
      The patient will required to follow a specific diet and to have a physical activity during&#xD;
      the study period ( 12 month).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent of total body weight loss (%TBWL) after 12 months</measure>
    <time_frame>12 month</time_frame>
    <description>Percent of TBWL from baseline (prior to EndoZip procedure) and 12 month post EndoZip</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with a reduction in %TBWL of at least 5% at 12 months.</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>EndoZip System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.&#xD;
Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoZip System</intervention_name>
    <description>The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.&#xD;
Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight.</description>
    <arm_group_label>EndoZip System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 21-70&#xD;
&#xD;
          2. BMI ≥ 30 and ≤40 kg/m².&#xD;
&#xD;
          3. Willingness to comply with the substantial behavioral modifications program as&#xD;
             required by the procedure.&#xD;
&#xD;
          4. Patients with history of failure with non-surgical weight-loss methods.&#xD;
&#xD;
          5. Willingness to follow protocol requirements, including signed informed consent,&#xD;
             routine follow-up schedule, completing laboratory tests, completing IWQOL&#xD;
             questionnaire and completing the medically supervised diet and behavior modification&#xD;
             program.&#xD;
&#xD;
          6. Residing within a reasonable distance from the investigator's office and able to&#xD;
             travel to the investigator to complete all routine follow- up visits.&#xD;
&#xD;
          7. Ability to give informed consent.&#xD;
&#xD;
          8. Women of childbearing potential (i.e., not post-menopausal or surgically sterilized)&#xD;
             must agree to use adequate birth control methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior surgery of any kind on the gastrointestinal tract (except uncomplicated&#xD;
             cholecystectomy or appendectomy).&#xD;
&#xD;
          2. Patients with history of small bowel or colonic obstruction, and/or adhesive&#xD;
             peritonitis and/or abdominal adhesions.&#xD;
&#xD;
          3. Patients with any inflammatory disease&#xD;
&#xD;
          4. Patients with history of cancer in the gastrointestinal tract.&#xD;
&#xD;
          5. Potential upper gastrointestinal bleeding conditions such as a history of&#xD;
             angioectasias.&#xD;
&#xD;
          6. A known gastric mass or gastric polyps &gt; 1 cm in size.&#xD;
&#xD;
          7. Patients with TG &gt;500 or LDL &gt;190&#xD;
&#xD;
          8. A known hiatal hernia &gt; 4cm of axial displacement of the z-line above the diaphragm or&#xD;
             severe or intractable gastro-esophageal reflux symptoms while on maximal medical&#xD;
             therapy.&#xD;
&#xD;
          9. A structural abnormality in the esophagus or pharynx such as a stricture or&#xD;
             diverticulum that could impede passage of the endoscope.&#xD;
&#xD;
         10. Patient with motility disorders of the GI tract or intractable constipation&#xD;
&#xD;
         11. Patients with known coagulation disorder (INR &gt;1.5) or on anticoagulation therapy.&#xD;
&#xD;
         12. Type 1 diabetes or Type 2 diabetes with a HgbA1c &gt;8 in 6 weeks prior the procedure or&#xD;
             use of any medication for diabetes other than metformin. Patients with any serious&#xD;
             health condition unrelated to their weight that would increase the risk of endoscopy&#xD;
&#xD;
         13. Patients with chronic abdominal pain&#xD;
&#xD;
         14. Patients with hepatic insufficiency or cirrhosis&#xD;
&#xD;
         15. Patients that used an intragastric device for weight loss within 2 years prior to this&#xD;
             study.&#xD;
&#xD;
         16. Patients with psychological health questionnaire-9 (PHQ-9) score of 10 or higher.&#xD;
&#xD;
         17. Patients receiving daily prescribed treatment with high dose aspirin (&gt; 100mg daily),&#xD;
             anti-inflammatory agents, anticoagulants or other gastric irritants.&#xD;
&#xD;
         18. Patients with history or current abuse of drugs or alcohol&#xD;
&#xD;
         19. Patients who are unable or unwilling to take prescribed proton pump inhibitor&#xD;
             medication&#xD;
&#xD;
         20. egg, milk, or wheat allergy (unable to go through the GEBT)&#xD;
&#xD;
         21. Patients who are pregnant or breast-feeding.&#xD;
&#xD;
         22. Patients who are taking medications that cause weight loss&#xD;
&#xD;
         23. Patients with Severe cardiopulmonary disease or other serious organic disease which&#xD;
             might include known history of coronary artery disease, Myocardial infarction within&#xD;
             the past 12 months, poorly-controlled hypertension, required use of NSAIDs&#xD;
&#xD;
         24. Patients taking medications on specified hourly intervals that may be affected by&#xD;
             changes to gastric emptying, such as anti-seizure or anti-arrhythmic medications&#xD;
&#xD;
         25. Patients who are taking corticosteroids, immunosuppressants, and narcotics&#xD;
&#xD;
         26. Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery&#xD;
             disease.&#xD;
&#xD;
         27. Pre-existing respiratory disease such as chronic obstructive pulmonary disease (severe&#xD;
             COPD), pneumonia or cancer.&#xD;
&#xD;
         28. Diagnosis of autoimmune connective tissue disorder (e.g. lupus, HIV, erythematous,&#xD;
             scleroderma) or immunocompromised.&#xD;
&#xD;
         29. Specific diagnosed genetic disorder such as Prader Willi syndrome (motility disorder)&#xD;
&#xD;
         30. Eating disorders including night eating syndrome (NES), bulimia, binge eating&#xD;
             disorder, or compulsive overeating&#xD;
&#xD;
         31. Known history of endocrine disorders affecting weight such as uncontrolled&#xD;
             hypothyroidism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravit Peled</last_name>
    <role>Study Director</role>
    <affiliation>NiTiNotes Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ravit Peled</last_name>
    <phone>+972 526145354</phone>
    <email>ravit@nitinotesurgical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gontrand N López, MD</last_name>
      <phone>+34 917567984</phone>
      <email>gontrandlopeznava@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna M Castillo</last_name>
      <phone>+34 913585236</phone>
      <email>secretaria@digestivolopeznava.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gontrand N López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

